Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 937 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Cancer in My Community: Accessing Care Through the Public Health System... May 9, 2023 Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... January 15, 2024 Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... October 8, 2025 A Poet’s Autobiography of Cancer May 31, 2023 Load more HOT NEWS Research with integrity – why colour blindness is a research integrity... Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... EMA Recommends Extension of Indications for Amivantamab Reducing Cancer’s Global Burden: A Conversation with NCI’s Dr. Satish Gopal
